These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2077517)

  • 1. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
    Lennard MS
    Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
    Meyer UA; Skoda RC; Zanger UM
    Pharmacol Ther; 1990; 46(2):297-308. PubMed ID: 2181495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
    J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Eur J Clin Pharmacol; 1997; 51(5):389-93. PubMed ID: 9049580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
    Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
    Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type.
    Adams M; Lennard MS; Otton SV; Tucker GT; Woods HF
    Biochem Pharmacol; 1991 Jul; 42(4):947-9. PubMed ID: 1867648
    [No Abstract]   [Full Text] [Related]  

  • 12. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
    Dayer P; Kronbach T; Eichelbaum M; Meyer UA
    Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debrisoquine/sparteine-type polymorphic drug metabolism in wild Clethrionomys rufocanus.
    Hoshi H; Masuda M; Yamamoto Y; Suimamoto Y; Kazusaka A; Fujita S
    Drug Metab Dispos; 1995 Nov; 23(11):1301-3. PubMed ID: 8591735
    [No Abstract]   [Full Text] [Related]  

  • 18. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 19. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
    Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
    Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
    Eichelbaum M; Gross AS
    Pharmacol Ther; 1990; 46(3):377-94. PubMed ID: 2188269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.